The impact of keratoconjunctivitis associated with meibomian gland dysfunction

Abstract

Meibomian gland dysfunction (MGD) is one of the most common ophthalmologic conditions worldwide. The clinical spectrum of the disease varies. Patients with mild MGD only experience chronic discomfort. Patients with severe dysfunction experience a decrease in vision and then become blind. The pathology of MGD involves meibomian gland destruction and an increase in lipid viscosity that blocks the pore, causing a reduction in glandular lipid secretion and discharge. This leads to a lack of the lipid layer in tear film, therefore causing damage to the ocular surface epithelial cells and inflammation. The keratoconjunctivitis associated with MGD occurs at the inferior corneal area that is in contact with the palpebral margin. Corneal tissue infiltrates the blood vessels. Some patients also suffer from acne and sebaceous gland disorder. Treatment includes cleaning the palpebral margin, supple artificial tear liquid, and treatment for infection and inflammation that prevents ocular tissue damage. Systemic medicine is necessary for patients with severe conditions. Complications need to be treated in a timely manner. Key words: Meibomian gland dysfunction; Keratoconjunctivitis; Inflammatory